CUMBERLAND PHARMACEUTICALS INC (CPIX)
2025-06-30 | 2024-09-30 | 2024-06-30 | ||
|---|---|---|---|---|
| Net revenues | 10,837,363 | 9,085,826 | 9,848,849 | |
| Selling and marketing | 4,223,647 | 4,397,480 | 4,248,401 | |
| Research and development | 1,468,399 | 1,306,095 | 1,059,187 | |
| General and administrative | 2,874,922 | 2,675,380 | 2,757,148 | |
| Cost of products sold | 2,011,389 | 1,323,013 | 1,710,944 | |
| Amortization | 1,006,484 | 1,078,290 | 1,099,857 | |
| Total costs and expenses | 11,584,841 | 10,780,258 | 10,875,537 | |
| Operating income (loss) | -747,478 | -1,694,432 | -1,026,688 | |
| Interest income | 127,489 | 69,190 | 61,841 | |
| Interest expense | 109,547 | 137,374 | 126,347 | |
| Other income - insurance proceeds | - | 237,089 | - | |
| Income (loss) before income taxes | -729,536 | -1,525,527 | -1,091,194 | |
| Income tax expense | 5,671 | 11,442 | 11,443 | |
| Net income (loss) | -735,207 | -1,536,969 | -1,102,637 | |
| Net loss (income) at subsidiary attributable to noncontrolling interests | 5,533 | 7,112 | -17,025 | |
| Net income (loss) attributable to common shareholders | -740,740 | -1,544,081 | -1,085,612 | |
| Basic (in shares) | 14,960,596 | 14,052,754 | 14,118,091 | |
| Basic (in usd per share) | -0.05 | -0.11 | -0.08 | |
| Diluted (in shares) | 14,960,596 | 14,052,754 | 14,118,091 | |
| Diluted (in usd per share) | -0.05 | -0.11 | -0.08 | |